Adding double carbapenem therapy to the armamentarium against carbapenem-resistant Enterobacteriaceae bloodstream
Bryan P White1, Smit Patel2, Janice Tsui3
1a OU Medical Center, Department of Pharmacy , Oklahoma City , Oklahoma , USA.
Background:
Carbapenem-resistant Enterobacteriaceae (CRE) constitute a threat, since they cause infections with high mortality rates. Historically, polymyxin-based therapies have been the regimens of choice for CRE bloodstream infection (BSI). Recent studies have shown improved outcomes with β-lactam-based therapies, including double carbapenem regimens for CRE BSIs compared to polymyxin-based regimens. The purpose of this report was to review the data supporting double carbapenem therapy for CRE BSI and provide recommendations regarding their use.
Methods:
A systematic literature search through 31 January 2018 was performed.
Results:
Multiple in vitro studies have described synergistic activity with ertapenem-based double carbapenem regimens for KPC-producing Enterobacteriaceae. Additionally, efficacy has been observed with double carbapenem regimens in multiple case reports and case series. A prospective multi-centre observational study of double carbapenem therapies in patients with CRE BSIs showed lower mortality compared to standard therapy.
Conclusions:
Clinicians should consider double carbapenem therapy as an option for treating CRE infections.
More Related Videos
11:12Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
Published on: September 13, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Resistivity
Resistance
Gene Therapy
Fixing Double-strand Breaks
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
